Novartis To Acquire Gene Therapy Provider Avexis For 8 7b In Cash

By themelower On Apr 13, 2026

Novartis To Acquire Gene Therapy Specialist Avexis For 8 7bn The New Basel, april 9, 2018 novartis announced today that it has entered into an agreement and plan of merger with avexis, inc. to acquire the us based nasdaq listed clinical stage gene therapy company for usd 218 per share or a total of usd 8.7 billion in cash. Novartis has struck an $8.7 billion deal to buy avexis. the move sees newly minted novartis ceo vas narasimhan, m.d., pay a hefty premium to establish the company as a frontrunner in the.

Novartis Buys Avexis For 8 7b Broadening Gene Therapy Bet Biopharma Novartis ag said april 9 it will buy the gene therapy focused biotech avexis inc. for $8.7 billion, greatly expanding the swiss pharma’s bet on the promise of treating disease by altering a patient’s genetic make up. Swiss pharmaceuticals company novartis plans to spend $8.7bn buying avexis, a us specialist in spinal muscular atrophy, a childhood wasting disease, in the latest strategic move by its new. Zurich (reuters) swiss drugmaker novartis is moving further into gene therapy by buying avexis for $8.7 billion, adding a rare disease treatment that could reap billions in sales. Novartis said today it has agreed to acquire avexis for $8.7 billion cash, in a deal intended to bolster both the buyer’s neuroscience portfolio and its presence in gene therapy with a promising.

Novartis Buys Avexis For 8 7b Broadening Gene Therapy Bet Biopharma Zurich (reuters) swiss drugmaker novartis is moving further into gene therapy by buying avexis for $8.7 billion, adding a rare disease treatment that could reap billions in sales. Novartis said today it has agreed to acquire avexis for $8.7 billion cash, in a deal intended to bolster both the buyer’s neuroscience portfolio and its presence in gene therapy with a promising. Novartis announced today that it has entered into an agreement and plan of merger with avexis, inc. to acquire the us based nasdaq listed clinical stage gene therapy company for usd 218 per share or a total of usd 8.7 billion in cash. Swiss drugmaker novartis said monday that it will acquire a chicago based gene therapy company that has been working on a new treatment for infants in an $8.7 billion deal. Swiss based novartis has struck a deal to acquire bannockburn, illinois based avexis for $8.7 billion. novartis will pay $218 per share, which is a 72 percent premium over avexis’s 30 day volume weighted average stock price. the deal is expected to close in mid 2018. On may 15, 2018, novartis announced its completed acquisition of avexis, a clinical stage gene therapy biotech company, for a total of $8.7 billion in cash through a merger of its indirect wholly owned subsidiary, novartis am merger corporation (merger sub), with and into avexis.

Indulge your senses in a gastronomic adventure that will tantalize your taste buds. Join us as we explore diverse culinary delights, share mouthwatering recipes, and reveal the culinary secrets that will elevate your cooking game in our Novartis To Acquire Gene Therapy Provider Avexis For 8 7b In Cash section.

FDA approves Novartis gene therapy for rare genetic disorder

FDA approves Novartis gene therapy for rare genetic disorder

FDA approves Novartis gene therapy for rare genetic disorder Novartis' $8.7 billion deal for gene therapy company AveXis Novartis buying AveXis for nearly $9 billion Novartis to release new gene therapy drug that could cost $2 million AveXis, A Novartis Company A gene therapy platform for treating diseases New frontiers of medicine – Cell and Gene Therapies how does gene therapy work - novartis' $8.7 billion deal for gene therapy company avexis Finding a "killer application" for novel biotech: AveXis case study Novartis Agrees $12 Billion Biotech Deal for Avidity Ep. 329 - Novartis' $12B Avidity Buy. Plus: Base Editors Novartis Cancer Drug Is Approved With $475,000 Price Tag IBRX: ImmunityBio FDA Resubmission Could 3X Anktiva's Cancer Market TX2763 - NOVARTIS FDA APPROVAL.mov This 11-year-old has battled a rare disease for years — a breakthrough drug helped deliver relief Is This the END of Huntington's Disease? Novartis and PTC's Plan Learn about Novartis Institutes for BioMedical Research Biotech's having a big day thanks to $9.7B acquisition by Novartis 825% Hand Improvement? NervGen NVG-291 SCI Final Results Are In. Plus Phase 3 Trial Announced!

Conclusion

In summation, our exploration of Novartis To Acquire Gene Therapy Provider Avexis For 8 7b In Cash has illuminated a range of insights and practical applications. From novice to expert, we trust that this content has furnished you with the necessary understanding to navigate this topic effectively.

We encourage you to explore further. To dive deeper into specific aspects, consult our expert resources. Your journey towards mastery of Novartis To Acquire Gene Therapy Provider Avexis For 8 7b In Cash is supported every step of the way. Join the conversation and help others learn.

Don't wait to implement what you've learned. Click here to discover more resources. The world of Novartis To Acquire Gene Therapy Provider Avexis For 8 7b In Cash is constantly evolving, and we're here to guide you through it. Let's continue this conversation and build something remarkable together. Your feedback is invaluable, so please let us know how we can further assist you.